Grifols S.A.
GRFS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for GRFS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GRFS
Grifols S.A. is a global plasma-derived therapies and diagnostics company with a vertically integrated U.S. plasma supply chain, reporting $7.2B revenue and $212.8M net income for FY2024, while carrying $10.6B in total debt.
Key risk: High debt leverage
BioSniper Score
Based on 5 of 6 signals
Financial data as of Dec 31, 2024.
Tracking 1 pipeline candidate · 24 clinical trials · 6 catalysts · 1 FDA decision for Grifols S.A..
Grifols S.A. is a global plasma-derived therapies and diagnostics company with a vertically integrated U.S. plasma supply chain, reporting $7.2B revenue and $212.8M net income for FY2024, while carrying $10.6B in total debt.
- Total revenue of $7,212.4M and net income of $212.8M for FY2024 [sec].
- Cash and equivalents of $974.7M as of 2024-12-31 [sec].
- Shareholders' equity of $7,513.7M and total debt of $10,642.1M as of 2024-12-31 [sec].
- Development costs in progress of €1,426M as of 2026-06-30, including €240M for neurodegenerative and other projects [sec · filed 2026-07-29].
- 1,379 scientists and support staff dedicated to R&D as of 2025-12-31 [sec · filed 2026-04-17].
What works
- Fully vertically integrated plasma supply chain in the U.S., providing flexibility in current market dynamics [sec · filed 2025-11-04].
- Strong commercial growth with +10.9% constant currency revenue growth in Q3 2025 [sec · filed 2025-11-04].
- Continuous improvement initiatives supporting margin expansion and free cash flow generation [sec · filed 2025-07-30].
- Pipeline execution with clinical trials traction across life cycle management and new products [sec · filed 2025-11-04].
What to weigh
- High leverage with total debt of $10,642.1M and a leverage ratio of 4.2x as of H1 2025 [sec · filed 2025-07-30].
- Significant competition from other plasma players and biosimilar products, which could affect immunoglobulin and other core franchises [sec · filed 2026-04-17].
- Substantial R&D spending required with no guarantee of successful product development or regulatory approval [sec · filed 2026-04-17].
- Large capital projects for facility expansion may run over budget or be delayed [sec · filed 2026-04-17].
From the filings
Quoted directly from source documents.
Grifols has a vertically integrated plasma supply chain in the U.S.
“Fully vertical integrated and well-invested in the US Complemented by strategic partnerships ex-US providing flexibility in current market dynamics”
SEC filings · November 4, 2025
Grifols faces significant competition from biosimilar products.
“We expect in the future to face greater competition from biosimilar products which could”
SEC filings · April 17, 2026
Grifols had €1,426 million in development costs in progress as of June 30, 2026.
“At 30 June 2026 the Group has an amount of Euros 1,426 million as development costs in progress (Euros 1,494 million at 31 December 2025).”
SEC filings · July 29, 2026
Grifols generated -€14M free cash flow (pre-M&A) in H1 2025.
“-€14m Free Cash Flow (pre-M&A)3 +€182m 4.2x Leverage ratio4 H1'25 H1'25 vs H1'24 -0.4x vs. FY24”
SEC filings · July 30, 2025
Catalyst timeline
- 2027-01-01 · Phase 3 Topline: A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Two Dose R — First of several Phase 3 readouts; results will inform efficacy and safety of a key pipeline candidate.
- 2027-09-30 · Phase 3 Topline: An Open-Label, Multicenter, Randomized, Non-Inferiority Pharmacokinetic and Safety/Tolerability Stud — Non-inferiority PK study; outcome will support potential label expansion or new product registration.
- 2027-12-31 · Phase 3 Topline: An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamun — Head-to-head PK/safety study for XEMBIFY; results may strengthen competitive positioning in IG franchise.
- 2028-08-31 · Phase 3 Topline: An Open-label, Multi-Center, Single-arm Prospective Clinical Trial to Evaluate Efficacy, Safety, and — Single-arm efficacy/safety trial; data will support regulatory submissions for a new indication.
- 2029-02-01 · Phase 3 Topline: An Open-Label, Multicenter Study to Evaluate the Long-term Safety of Weekly Intravenous Alpha1-Prote — Long-term safety data for Alpha-1 IV formulation; critical for chronic therapy adoption.
- 2029-08-01 · Phase 3 Topline: A Randomized, Multi-Center, Parallel, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate — Placebo-controlled efficacy trial; outcome will determine potential for a new therapeutic area entry.
Risks & what to watch (4)›
Key risks
- High debt leverage — Total debt of $10.6B and leverage ratio of 4.2x as of H1 2025, requiring sustained cash flow for deleveraging [sec · filed 2025-07-30].
- Clinical trial and regulatory delays
- Intense competition
- Capital project overruns
What to watch
- Progress on deleveraging and free cash flow generation, especially after H1 2025 negative FCF [sec · filed 2025-07-30].
- Clinical trial readouts for pipeline programs, including Phase 3 top-line data expected from 2027 onward [sec].
- Impact of IRA and potential tariffs on revenue and margin expansion [sec · filed 2025-11-04].
- Execution of the Diagnostic business transformation plan and its effect on profitability [sec · filed 2026-02-26].
Sources: SEC filings · Generated August 28, 2026 · How we verify sources →
Run Grifols S.A. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Grifols S.A. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Profitable (positive operating cash flow)
D/E 1.49
Lead: Approved
1 candidate
6 upcoming, next in ~124d
No insider transactions in the last 180 days
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
181
Total value held
$895.6M
| Holder | Shares | Value |
|---|---|---|
| brandes investment partners, lp | 36,333,714 | $291.4M |
| permian investment partners, lp | 19,354,679 | $155.2M |
| janus henderson group plc | 6,580,178 | $52.7M |
| millennium management llc | 5,005,532 | $40.1M |
| bank of america corp /de/ | 4,327,413 | $34.7M |
| armistice capital, llc | 2,988,000 | $24.0M |
| morgan stanley | 2,857,956 | $22.9M |
| arrowstreet capital, limited partnership | 2,723,385 | $21.8M |
| jpmorgan chase & co | 2,701,572 | $20.4M |
| bank of montreal /can/ | 2,506,278 | $20.1M |
Showing top 10 of 181 institutional holders of Grifols S.A.. Open the full 13F history after sign-in.
Frequently asked questions
What is the AI investment thesis for Grifols S.A.?
Grifols S.A. is a global plasma-derived therapies and diagnostics company with a vertically integrated U.S. plasma supply chain, reporting $7.2B revenue and $212.8M net income for FY2024, while carrying $10.6B in total debt.
What is Grifols S.A.'s lead drug candidate?
Grifols S.A.'s most advanced tracked candidate is sodium chloride 0.9% in plastic container (Approved).
What is Grifols S.A.'s next catalyst?
Grifols S.A.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Two Dose R" — expected January 1, 2027.
Who is the CEO of Grifols S.A.?
Mr. Jose Ignacio Abia Buenache is the chief executive officer of Grifols S.A. (GRFS).
Where is Grifols S.A. headquartered?
Grifols S.A. (GRFS) is headquartered in Barcelona, Spain.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.